These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 32969287)

  • 1. Specific Therapy for Transthyretin Cardiac Amyloidosis: A Systematic Literature Review and Evidence-Based Recommendations.
    Marques N; Azevedo O; Almeida AR; Bento D; Cruz I; Correia E; Lourenço C; Lopes LR
    J Am Heart Assoc; 2020 Oct; 9(19):e016614. PubMed ID: 32969287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
    Benbrahim M; Norman K; Sanchorawala V; Siddiqi OK; Hughes D
    J Cardiovasc Pharmacol; 2021 May; 77(5):544-548. PubMed ID: 33657048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
    Maurer MS; Schwartz JH; Gundapaneni B; Elliott PM; Merlini G; Waddington-Cruz M; Kristen AV; Grogan M; Witteles R; Damy T; Drachman BM; Shah SJ; Hanna M; Judge DP; Barsdorf AI; Huber P; Patterson TA; Riley S; Schumacher J; Stewart M; Sultan MB; Rapezzi C;
    N Engl J Med; 2018 Sep; 379(11):1007-1016. PubMed ID: 30145929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Specific pharmacological treatment guide for transthyretin amyloid cardiomyopathy, 2021].
    Villanueva E; Carretero M; Aguirre MA; Negro A; Belziti CA; Posadas-Martínez ML; Nucifora EM; Baratta S; Costabel JP; Higa C; Rivas C; Fernández A; Quiroga A; Dumont CA; Volberg VI; Streitenberg GM; Perez de Arenaza D
    Medicina (B Aires); 2022; 82(2):275-288. PubMed ID: 35417392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
    Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
    Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy.
    Kazi DS; Bellows BK; Baron SJ; Shen C; Cohen DJ; Spertus JA; Yeh RW; Arnold SV; Sperry BW; Maurer MS; Shah SJ
    Circulation; 2020 Apr; 141(15):1214-1224. PubMed ID: 32078382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Systematic Review of Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
    Singh BM; Bohara N; Gautam K; Basnet M; Kc S; Kc B; Raut A; Phudong A; Gautam J
    Cureus; 2021 Sep; 13(9):e18221. PubMed ID: 34703707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy?
    Müller ML; Butler J; Heidecker B
    Eur J Heart Fail; 2020 Jan; 22(1):39-53. PubMed ID: 31912620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
    Solomon SD; Adams D; Kristen A; Grogan M; González-Duarte A; Maurer MS; Merlini G; Damy T; Slama MS; Brannagan TH; Dispenzieri A; Berk JL; Shah AM; Garg P; Vaishnaw A; Karsten V; Chen J; Gollob J; Vest J; Suhr O
    Circulation; 2019 Jan; 139(4):431-443. PubMed ID: 30586695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
    Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H
    Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
    [No Abstract]   [Full Text] [Related]  

  • 11. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
    Rubin J; Maurer MS
    Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac Amyloidosis Treatment.
    Stern LK; Patel J
    Methodist Debakey Cardiovasc J; 2022; 18(2):59-72. PubMed ID: 35414852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.
    Endo J; Sano M; Izumiya Y; Tsujita K; Nakamura K; Tahara N; Kuwahara K; Inomata T; Ueda M; Sekijima Y; Ando Y; Tsutsui H; Isobe M; Fukuda K
    Circ J; 2019 Dec; 84(1):15-17. PubMed ID: 31735731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnosis and treatment of cardiac transthyretin amyloidosis. Innovative therapy with tafamidis.].
    Legrand D; Nyssen A; Jackers L; Brogneaux C; Pirotte I; Grayet D; Lacremans D; Magnée M
    Rev Med Liege; 2022 Jan; 77(1):63-68. PubMed ID: 35029343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.
    Rigopoulos AG; Ali M; Abate E; Torky AR; Matiakis M; Mammadov M; Melnyk H; Vogt A; de Vecchis R; Bigalke B; Wohlgemuth W; Mavrogeni S; Noutsias M
    Heart Fail Rev; 2019 Jul; 24(4):521-533. PubMed ID: 30790171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent progress in the understanding and treatment of transthyretin amyloidosis.
    Sekijima Y
    J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction.
    Griffin JM; Maurer MS
    Trends Cardiovasc Med; 2021 Jan; 31(1):59-66. PubMed ID: 31889610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.
    Shintani Y; Okada A; Morita Y; Hamatani Y; Amano M; Takahama H; Amaki M; Hasegawa T; Ohta-Ogo K; Kanzaki H; Ishibashi-Ueda H; Yasuda S; Shimazaki C; Yoshinaga T; Yazaki M; Sekijima Y; Izumi C
    ESC Heart Fail; 2019 Feb; 6(1):232-236. PubMed ID: 30478886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of diflunisal for transthyretin cardiac amyloidosis: a review.
    Ibrahim M; Saint Croix GR; Lacy S; Fattouh M; Barillas-Lara MI; Behrooz L; Mechanic O
    Heart Fail Rev; 2022 Mar; 27(2):517-524. PubMed ID: 34272629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.